Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype

Página do item simplificado
dc.contributor.authorSader, Helio S.
dc.contributor.authorHsiung, Andre
dc.contributor.authorFritsche, Thomas R.
dc.contributor.authorJones, Ronald N.
dc.contributor.institutionJMI Labs
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionHardy Diagnost
dc.contributor.institutionTufts Univ
dc.date.accessioned2016-01-24T12:41:55Z
dc.date.available2016-01-24T12:41:55Z
dc.date.issued2007-03-01
dc.description.abstractCefepime exhibits more stability to hydrolysis by extended-spectrum beta-lactamases (ESBLs) compared with other cephalosporins, and piperacillin/tazobactam may be active against these pathogens because of the enzyme inhibitory activity of tazobactam. Thus, we evaluated the in vitro activity of these 2 antimicrobials against a large collection of isolates with an ESBL phenotype. A total of 50,637 clinical isolates (34,367 Escherichia coli and 16,270 Klebsiella spp.) collected from more than 80 medical centers (1998-2004) were tested by reference broth microdilution methods, and isolates with an ESBL phenotype (MIC, >= 2 mu g/mL for aztreonam or ceftazidime or ceftriaxone) were submitted to a clavulanate inhibition test (confirmation of ES13L production). Among isolates from North America, 3.9% of E. coli and 8.6% of Klebsiella spp. showed an ES13L phenotype, whereas among isolates from the rest of the world (ROW) (Europe, Latin America, and Asia), 7.7% of E. coli and 28.3% of Klebsiella spp. exhibited this pattern. Confrmation rates varied from 21.6% of E. coli in North America to 52.8% of Klebsiella spp. in the row. Among E. coli from North America, cefepime (90.3% susceptibility) was generally more active than piperacillin/tazobactam (82.7%), especially among ESBL-not-confirmed (97.0% versus 85.5%). Cefepime also showed reasonable activity against Klehsiella spp. from North America (89.4% susceptibility). in general, isolates from North America exhibited higher susceptibility rates to both beta-lactams compared with isolates from the ROW, and ESBL-not-confirmed strains showed generally higher susceptibility rates than ESBL-confirmed organisms. (c) 2007 Elsevier Inc. All rights reserved.en
dc.description.affiliationJMI Labs, N Liberty, IA 52317 USA
dc.description.affiliationUniversidade Federal de São Paulo, BR-04023900 São Paulo, Brazil
dc.description.affiliationHardy Diagnost, Santa Maria, CA 93455 USA
dc.description.affiliationTufts Univ, Sch Med, Boston, MA 02111 USA
dc.description.affiliationUnifespUniversidade Federal de São Paulo, BR-04023900 São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent341-344
dc.identifierhttp://dx.doi.org/10.1016/j.diagmicrobio.2006.08.016
dc.identifier.citationDiagnostic Microbiology and Infectious Disease. New York: Elsevier B.V., v. 57, n. 3, p. 341-344, 2007.
dc.identifier.doi10.1016/j.diagmicrobio.2006.08.016
dc.identifier.issn0732-8893
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/29545
dc.identifier.wosWOS:000245221300018
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofDiagnostic Microbiology and Infectious Disease
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.rights.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.subjectESBLen
dc.subjectKlebsiellaen
dc.subjectEscherichia colien
dc.subjectcefepimeen
dc.subjectpiperacillin/tazobactamen
dc.titleComparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotypeen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
Em verificação - Geral